To evaluate the significant response biomarker, the KEYNOTE-028 (NCT02054806) study analyzed multiple biomarkers including expression of an 18-gene T cell-inflamed profile, PD-L1 expression, and tumor mutational burden. This evidence concerns the gene CD274 and neoplasm.